Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise
- PMID: 11762557
- DOI: 10.1177/00912700122012887
Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise
Abstract
The objectives of this randomized, open-label, three-period, incomplete block design study were to evaluate the pharmacokinetics of norelgestromin (NGMN) and ethinyl estradiol (EE) delivered by the contraceptive patch, Ortho Evra/Evra, and to evaluate patch adhesion under conditions of heat, humidity, and exercise. During each treatment period, 30 healthy women wore Ortho Evra on the abdomen for 7 days under one of six conditions (normal activity, sauna, whirlpool, treadmill, cool water immersion, or a combination of activities). Blood samples were collected before and several times to 240 hours after patch application. Mean serum concentrations of NGMN and EE generally remained within the reference ranges, 0.6 to 1.2 ng/ml and 25 to 75 pg/ml, respectively, during the 7-day wearperiodfor all activities. Only 1 (1.1%) of 87 patches completely detached spontaneously. Peel force measurements were comparable for all activities. Ortho Evra was well tolerated. In conclusion, Ortho Evra delivers efficacious concentrations of NGMN and EE and maintains adhesive reliability through 7 days of wear even under conditions of heat, humidity, and exercise.
Similar articles
-
Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches.J Clin Pharmacol. 2001 Nov;41(11):1232-7. doi: 10.1177/00912700122012788. J Clin Pharmacol. 2001. PMID: 11697756 Clinical Trial.
-
Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites.Br J Clin Pharmacol. 2002 Feb;53(2):141-6. doi: 10.1046/j.0306-5251.2001.01532.x. Br J Clin Pharmacol. 2002. PMID: 11851637 Free PMC article. Clinical Trial.
-
Pharmacokinetic overview of Ortho Evra/Evra.Fertil Steril. 2002 Feb;77(2 Suppl 2):S3-12. doi: 10.1016/s0015-0282(01)03261-7. Fertil Steril. 2002. PMID: 11849630 Review.
-
Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions.Fertil Steril. 2002 Feb;77(2 Suppl 2):S32-5. doi: 10.1016/s0015-0282(01)03262-9. Fertil Steril. 2002. PMID: 11849634
-
Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.Treat Endocrinol. 2003;2(3):191-206. doi: 10.2165/00024677-200302030-00005. Treat Endocrinol. 2003. PMID: 15966567 Review.
Cited by
-
Heat effects on drug delivery across human skin.Expert Opin Drug Deliv. 2016;13(5):755-68. doi: 10.1517/17425247.2016.1136286. Epub 2016 Jan 25. Expert Opin Drug Deliv. 2016. PMID: 26808472 Free PMC article. Review.
-
Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.Int J Clin Pharmacol Ther. 2014 Dec;52(12):1059-70. doi: 10.5414/CP202064. Int J Clin Pharmacol Ther. 2014. PMID: 25295716 Free PMC article. Clinical Trial.
-
Effect of missed combined hormonal contraceptives on contraceptive effectiveness: a systematic review.Contraception. 2013 May;87(5):685-700. doi: 10.1016/j.contraception.2012.08.035. Epub 2012 Oct 22. Contraception. 2013. PMID: 23083527 Free PMC article.
-
New and emerging contraceptives: a state-of-the-art review.Int J Womens Health. 2014 Feb 19;6:221-34. doi: 10.2147/IJWH.S46811. eCollection 2014. Int J Womens Health. 2014. PMID: 24570597 Free PMC article. Review.
-
U.S. Selected Practice Recommendations for Contraceptive Use, 2024.MMWR Recomm Rep. 2024 Aug 8;73(3):1-77. doi: 10.15585/mmwr.rr7303a1. MMWR Recomm Rep. 2024. PMID: 39106301 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical